Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- All Clinical Studies Need to Be Conducted According to Global Standards: Expert Committee
June 27, 2011
- Lenvatinib Shows ORR of 59% in Global PII: Eisai
June 27, 2011
- Merck to License Biosimilar of Enbrel from Hanwha of South Korea
June 27, 2011
- Daiichi Sankyo Confident about Independently Expanding Share for Memary
June 27, 2011
- Korosho to Enhance Generics' Reliability: Minister Hosokawa
June 27, 2011
- PIII Study Confirms Safety, Efficacy of Rotigotine Patch: Otsuka
June 27, 2011
- Mr Yoshida Points Out Need to Review NHI Pricing Rules for Generics
June 27, 2011
- New Prescription of Actos Suspended in France, Germany due to Bladder Cancer Risk
June 20, 2011
- Development of Anti-obesity Drug Contrave Suspended in US
June 20, 2011
- Chuikyo to Resume Discussions on Next Round of Drug Pricing Reform on June 22
June 20, 2011
- Agensys, Seattle Genetics to Codevelop ADC ASG-22ME: Astellas
June 20, 2011
- PMDA Accelerating Preparations for Membership in PIC/S
June 20, 2011
- DSP, TRANS GENIC, Univ. of Tokyo Sign Joint Research Agreement for AIM
June 20, 2011
- Concern Growing About Gov't Plan to Revise Patients' Drug Copayments
June 20, 2011
- Fujitsu, Univ. of Tokyo to Jointly Develop Technology for Creating LMW Compounds
June 20, 2011
- Fuso Applies for Surgical Hemostatic Product
June 20, 2011
- OncoTherapy Closes Patient Enrollment for PII Trial of OTS102 for Biliary Tract Cancer
June 20, 2011
- CellSeed Applies for Epithelial Cell Sheet for Corneal Regeneration
June 20, 2011
- FDA Not to Require PIII Data on Intranasal Granisetron: SNBL
June 20, 2011
- Daiichi Sankyo: Novel AD Treatment Memary Tablets
June 20, 2011
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…